Viatris has officially divested its Tyrvaya (varenicline solution) nasal spray business, transferring the asset to Harrow. Tyrvaya is an FDA-approved treatment for the signs and symptoms of dry eye disease. For Viatris, the sale is part of a broader strategy to streamline its operations and focus on its core therapeutic areas. By offloading this asset, Viatris aims to reduce complexity within its portfolio.

For Harrow, the acquisition represents a significant expansion of its ophthalmic portfolio. Harrow specializes in eye care products and intends to leverage its existing commercial infrastructure to grow Tyrvaya’s market presence. The company views the nasal spray as a key growth engine that complements its current offerings. While Viatris is moving away from the asset, Harrow is positioning itself to capture more of the dry eye treatment market. Analysts are currently evaluating whether Harrow’s specialized sales force can successfully scale the product more effectively than Viatris did, given Harrow's singular focus on the ophthalmic sector compared to Viatris's diversified pharmaceutical business model.